Arbutus Biopharma Corp Operating Lease Cost
Arbutus Biopharma Corp (ABUS) reported Operating Lease Cost of $300.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-23
- Arbutus Biopharma Corp operating lease, cost for fiscal 2025 was $300.00K, a 57.14% decline from fiscal 2024.
- Arbutus Biopharma Corp operating lease, cost for fiscal 2024 was $700.00K, a 16.67% increase from fiscal 2023.
- Arbutus Biopharma Corp operating lease, cost for fiscal 2023 was $600.00K, a 14.29% decline from fiscal 2022.
- Arbutus Biopharma Corp operating lease, cost for fiscal 2022 was $700.00K.
| Period end | Operating Lease, Cost 12 month |
|---|---|
| 2025-12-31 | $300.00K 10-K · filed 2026-03-23 |
| 2024-12-31 | $700.00K 10-K · filed 2026-03-23 |
| 2023-12-31 | $600.00K 10-K · filed 2025-03-27 |
| 2022-12-31 | $700.00K 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |